TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has issued an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. held its Annual General Meeting on May 28, 2025, where all proposed resolutions were approved by shareholders. The meeting saw the appointment of Mr. Zhang Ruliang as an executive director and Ms. Fu Dawei as a non-executive director, along with the re-election of Dr. Tian Wenzhi as an executive director. These decisions are expected to strengthen the company’s leadership and potentially enhance its strategic direction in the biopharmaceutical industry.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in Shanghai, China, focusing on the development of innovative cancer immunotherapy treatments. The company is involved in the research and development of biopharmaceutical products aimed at enhancing the immune system’s ability to combat cancer.
Average Trading Volume: 4,543,278
Technical Sentiment Signal: Hold
Current Market Cap: HK$8.25B
For detailed information about 1541 stock, go to TipRanks’ Stock Analysis page.